Novo Nordisk A/S
Bagsværd, Denmark, 12 May 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk.
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name of the Board member/Executive/Associated Person
Caroline Munk Esbjerg
2
Reason for the notification
a)
Position/status
Closely associated person to Karsten Munk Knudsen, Executive Vice President, Chief Financial Officer (CFO)
b)
Initial notification/Amendment
Initial notification
3
Details of the issuer
a)
Name
Novo Nordisk A/S
b)
LEI
549300DAQ1CVT6CXN342
4
Details of the transaction(s)
a)
Description of the financial instrument,
type of instrument,
Shares
Identification code
Novo Nordisk B DK0062498333
b)
Nature of the transaction
Shares received as gift
c)
Price(s) and volume(s)
Price(s)
Volume(s)
DKK 294.30
50
d)
Aggregated information
50 shares
DKK 14,715
e)
Date of the transaction
2026-05-07
f)
Place of the transaction
Outside a trading venue
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name of the Board member/Executive/Associated Person
Sofie Munk Esbjerg
2
Reason for the notification
a)
Position/status
Closely associated person to Karsten Munk Knudsen, Executive Vice President, Chief Financial Officer (CFO)
b)
Initial notification/Amendment
Initial notification
3
Details of the issuer
a)
Name
Novo Nordisk A/S
b)
LEI
549300DAQ1CVT6CXN342
4
Details of the transaction(s)
a)
Description of the financial instrument,
type of instrument,
Shares
Identification code
Novo Nordisk B DK0062498333
b)
Nature of the transaction
Shares received as gift
c)
Price(s) and volume(s)
Price(s)
Volume(s)
DKK 294.25
50
d)
Aggregated information
50 shares
DKK 14,712.50
e)
Date of the transaction
2026-05-07
f)
Place of the transaction
Outside a trading venue
About Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 67,900 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube